Patient Education Sheet Library
Search Results
Downloads
Download (English) – 0.35MBIsatuximab and VRd
The combination of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) is used for multiple myeloma.
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads
Brentuximab Vedotin, Lenalidomide, and Rituximab
The combination of brentuximab vedotin, lenalidomide, and rituximab is used for certain lymphomas.
Treatment Given by Infusion Treatment Taken by MouthDownloads
Amivantamab and Lazertinib
The combination of amivantamab and lazertinib is used lung cancer.
Treatment Given by Infusion Treatment Taken by MouthDownloads
Lenvatinib and Pembrolizumab
The combination of lenvatinib and pembrolizumab is used for kidney cancer and endometrial cancer.
Treatment Given by Infusion Treatment Taken by MouthDownloads
Axitinib and Pembrolizumab
The combination of axitinib and pembrolizumab is used for kidney cancer.
Treatment Given by Infusion Treatment Taken by MouthDownloads
Dostarlimab, Carboplatin, and Paclitaxel
The combination of dostarlimab, carboplatin, and paclitaxel is used for endometrial cancer.
Treatment Given by InfusionDownloads
Enfortumab Vedotin and Pembrolizumab
The combination of enfortumab vedotin and pembrolizumab is used for bladder cancer and cancers of…
Treatment Given by InfusionDownloads
Daratumumab and KRd
The combination of daratumumab and KRd (carfilzomib, lenalidomide, and dexamethasone) is used for multiple myeloma.
Treatment Given by Infusion Treatment Taken by MouthDownloads
Daratumumab and VRd
The combination of daratumumab and VRd (bortezomib, lenalidomide, and dexamethasone) is used for multiple myeloma.
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads
Popular Searches
PES Review Committee
The Patient Education Sheet (PES) Committee is a multidisciplinary team of oncology professionals who guide the development and review of these important resources. This committee ensures that every PES is accurate, clear, and meaningful for patients and caregivers navigating cancer treatment.
Led by NCODA and supported through collaboration with three leading professional organizations—ACCC, HOPA, and ONS—the committee combines expertise from across the oncology care spectrum. Together, they uphold best practices, promote consistency in patient education, and remain committed to improving outcomes through accessible, patient-centered information.
